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Abstract
Background: Moraxella catarrhalis is an important bacterial patho-
gen. However, no data regarding this human pathogenare currently 
available in Lebanon. This study aimed to determine for the first time 
the antimicrobial susceptibility profiles of M. catarrhalis isolates in Le-
banon.
Methods: A total of 34 M. catarrhalis strains were isolated from 
clinical specimensduring the period from November 2010 to March 
2019. Bacterial identification was performed using MALDI-TOF MS. 
Antibiotic susceptibility of allisolates was interpreted according to EU-
CAST recommendations.
Results: A total of 34 non-duplicated M. catarrhalis strains were iso-
lated from patients referred to Nini Hospital in Tripoli, Lebanon. Regar-
ding antibiotic susceptibility rates, the percent susceptibility is 100% 
to the majority of antibiotics, except ampicillin (7.4%), trimethoprim-
sulfamethoxazole (85.3%), nalidixic acid (85.3%), and ciprofloxacin 
(97.1%).
Conclusion: To our knowledge, this study is the first investigation 
regarding the antimicrobial susceptibility patterns of M. catarrhalis iso-
lates in Lebanon. In addition to the high level of resistance to ampici-
llin, our findings showed the emergence of resistance to trimethoprim-
sulfamethoxazole, nalidixic acid and ciprofloxacin. Even if this study 
provides useful information to develop effective empirical treatment, 
we recommend the implementation of reliable diagnostic tools to 
guide appropria tetreatment.
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Introduction
Moraxella catarrhalis is an aerobic Gram-negative 
diplococcus, formerly known as Branhamella cata-
rrhalis, that resides exclusively in humans, and com-
mensally colonizes the mucosal surface of the upper 
respiratory tract, and occasionally the conjunctiva 
and genital tract [1]. The highest prevalence of colo-
nization was detected among infants and children, 
which decreased in healthy adults [2]. The role of 
this bacterium as a disease-causing organism has 
long been questioned. M. catarrhalis was recogni-
zed to cause occasionally infections such as acute 
otitis media, sinusitis, acute bronchitis, pneumonia, 
and exacerbations of chronic obstructive pulmonary 
disease, and rarely bacteremia, meningitis, septic ar-
thritis, osteomyelitis, endocarditis, and pericarditis, 
especially in immunocompromised persons [3]. In 
fact, the absence of vaccines for prevention and 
the low number of active antibiotics for treatment 
of M. catarrhalis infections, have considered this 
bacterium as an important human pathogen [4]. 
In addition, two major resistance mechanisms have 
been described in M. catarrhalis: the inactivation of 
antimicrobials by enzymes such as β-lactamases and 
the decrease in permeability of bacterial cell wall 
(reducing in the number of porins and/or enhance-
ment of the active efflux system) [1]. The beta-lacta-
mase-producing M. catarrhalis was firstly reported 
in 1976. Today, two distinct BRO-type β-lactamase 
enzymes (BRO-1 and BRO-2), have been reported 
worldwide [5]. Regrettably, BRO-positive M. catarr-
halis strains have increased rapidly in recent years, 
and are now accounting for more than 90% globally 
[2]. The evidence of continuing misuse of antibiotics 
associated with a low level of antibiotic awareness 
is of global concern [6]. In Lebanon, as other deve-
loping countries, national investigations showed an 
increase in the levels of antimicrobial resistance in 
clinical and non-clinical settings [7-11]. For instance, 
a recent nationwide study conducted in 13 different 
hospitals located in different Lebanese governorates 
showed a trend of increasing antimicrobial resistan-
ce [12]. Even if the epidemiology of antimicrobial 
resistance is widely studied in Lebanon, there is a 
lack of studies on antimicrobial resistance in M. ca-
tarrhalis isolates in this country. Therefore, we de-
cided to assess for the first time the antimicrobial 
resistance patterns in M. catarrhalis strains isolated 
in North Lebanon.
Material and Methods
This study was conducted in the clinical microbio-
logy laboratory of Nini Hospital during the period 
from November 2010 to March 2019. The isolation 
of M. catarrhalis strains was performed according 
to standard protocols proposed by the Référentielen 
Microbiologie Médicale (REMIC) using a calibrated 
loop (10 µl) and a blood agar (Bio-Rad®, France) 
after an incubation for 18 to 24 hours at 35°C in 
air enriched with 5% CO2. Bacterial identification 
was carriedout through the use of API-NH (bio-
Mérieux, Marcy l'Etoile, France). All isolates were 
transferred to the Laboratoire Microbiologie Santé 
et Environnement (LMSE) at the Lebanese Universi-
ty for identification confirmation or exclusion using 
matrix assisted laser desorption ionization-time of 
flight mass spectrometry (MALDI-TOF-MS) (bioMé-
rieux, Marcy l'Etoile, France). The antibiotic suscepti-
bility testing was performed for M. catarrhalis isola-
tes by the disk diffusion method on Mueller Hinton 
supplemented with 5% blood and 20 mg/l β-NAD 
(MH-F) according to the recommendations of the 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST). The antibiotics tested were ampi-
cillin (AMP; 2 µg), amoxicillin - clavulanic acid (AMC; 
2-1 µg), cefotaxime (CTX; 5 µg), cefixime (CFM; 5 
µg), tetracycline (TET; 30 µg), minocycline (MNO; 30 
µg), erythromycin (E; 15 µg), chloramphenicol (C; 30 
µg), nalidixic acid (NA; 30 µg), ciprofloxacin (CIP; 5 
µg) and trimethoprim-sulfamethoxazole (SXT; 1.25-
23.75 µg).
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Results
This study was conducted in the North governorate 
of Lebanon. A total of 34 non-duplicated M. cata-
rrhalis isolates were recovered from patients refe-
rred to Nini Hospital. Overall, M. catarrhalis strains 
were isolated from nose (n=19), ear (n=7), sputum 
(n=5), blood (n=1), eye (n=1), and throat (n=1) of 
34 patients (23 malesand 11 females, ranging in 
age from 2 weeks to 77 years, with a mean age 
of 11.9 years) presenting respiratory like symptoms.
Regarding antibiotic susceptibility rates, the percent-
susceptibility is 100% to the majority of antibio-
tics, such as amoxicillin-clavulanic acid, cefotaxime, 
cefixime,tetracycline, minocycline, erythromycin, 
and chloramphenicol (Table 1). Higher antibioticre-
sistance rates were observed to ampicillin (92.6%), 
trimethoprim-sulfamethoxazole (14.7%), nalidixic 
acid (14.7%), and ciprofloxacin (2.9%) (Figure 1).
Discussion
The global increase in the prevalence of M. catarr-
halis in recent years has drawn the attention to the 
clinical importance of this bacterium, particularly as 
an important cause of respiratory tract infections 
[13]. The present surveillance study in North Leba-
non aimed to evaluate the susceptibility patterns of 
M. catarrhalis clinical isolates to several commonly 
used antibiotic agents in the hopes of helping phy-
sicians and infectious diseases specialists in deve-
loping effective empirical antibiotic treatment for 
M. catarrhalis infections. These bacteria are almost 
universally capable of producing of one of two 
chromosomally encoded BRO β-lactamases, with 
previous investigations showing production in more 
than 90% of clinical isolates [2, 14-16]. As expected, 
the present finding (92.6% of isolates are ampicillin 
resistant) is compatible with previous investigations 
(Table 2). This dramatic increase in the prevalence of 
ampicillin resistant M. catarrhalis strains could be re-
garded as the fastest dissemination of β-lactamase 
genes within the genus. The BRO genes appear to 
be chromosomally located but are readily transfe-
rred by conjugation with in the Moraxella species. 
Besides the high level of resistance to penicillin, the 
combination of penicillin with a β-lactamase inhibi-
tor used as a treatment of M. catarrhalis infections 
is still active against 100% of our isolates in almost 
all countries. However, unfortunately, recent studies 
found the emergence of M. catarrhalis strains resis-
Table 1.  Distribution of Moraxella catarrhalis isolates according to clinical specimens, and their antibiotic 
resistance patterns.
Antibiotic agents (% of resistance)
Specimen N AMP AMC CTX CFM E TET MNO C NA CIP SXT
Nose 19 84.2 0 0 0 0 0 0 0 15.8 0 15.8
Ear 7 100 0 0 0 0 0 0 0 14.3 0 28.6
Sputum 5 100 0 0 0 0 0 0 0 20 20 0
Blood 1 100 0 0 0 0 0 0 0 0 0 0
Eye 1 100 0 0 0 0 0 0 0 0 0 0
Throat 1 100 0 0 0 0 0 0 0 0 0 0
Ampicillin (AMP); Amoxicillin - clavulanic acid (AMC);Cefotaxime (CTX); Cefixime (CFM); Erythromycin (E); etracycline (TET); 
Minocycline (MNO); Chloramphenicol (C); Nalidixic acid (NA); Ciprofloxacin (CIP); Trimethoprim-sulfamethoxazole (SXT).
Figure 1:  Antibiotic susceptibility rates of Moraxe-
lla catarrhalis isolates.
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tant to amoxicillin-clavulanic acid and third genera-
tion cephalosporins [17]. 
Other antimicrobial agents, such as tetracycline, 
erythromycin, ciprofloxacin, and trimethoprim-sul-
famethoxazole have also been empirically used to 
treat M. catarrhalis infections worldwide with appa-
rent success. All clinical isolates collected in this stu-
dy showed 100% susceptibility to tetracycline and 
erythromycin which is consistent with the most 
current international research [18]. Nevertheless, 
the antimicrobial resistance threat must keep the 
clinical community vigilant. Regrettably, tetracycli-
ne resistance has emerged in numerous developing 
and developed countries. The higher levels of resis-
tance were reported in China [19], Taiwan [2] and 
Ethiopia [20]. Furthermore, several studies realized 
in developing countries indicated unexpected levels 
of antimicrobial resistance to erythromycin in M. ca-
tarrhalis isolates, with 59.1% in Pakistan [13], 70.8% 
in China [19], and 86.6% in Ethiopia [20]. 
On the other hand, our findings showed the 
emergence of resistance to trimethoprim-sulfa-
methoxazole (14.7%), and ciprofloxacin (2.9%).
Various previous studies conducted globally repor-
ted the spread of resistance to trime thoprim-sul-
famethoxazole among M. catarrhalis isolates, such 
as 12.5% in Tunisia [21], 13.8% in Australia [22], 
15.7% in Canada [23], 18.5% in Taiwan [2], 28.1% 
in China [19], 28.4% in Greece [24], 59% in Pakistan 
[13], 78.4% in Ethiopia [20], and 100% in Iran [25]. 
Based on the aforementioned data, the spread of 
cotrimoxazole resistance among M. catarrhalis isola-
tes in developing countries is shocking, and reveals a 
prominent threat jeopardizing the clinical efficacy of 
this important antibiotic. Moreover, the ciprofloxa-
cin resistancewas detected for the first time among 
Table 2.  Worldwide available data regarding the percentage of resistance of Moraxella catarrhalis isolates 
to major antibiotics.
Antibiotic agents
Country Year AMP AMC CTX E TET CIP SXT Ref.
Australia 2010 63.6 0 0 0 1.1 0 13.8 22
United States 2012 96.4 0 0.2 0.5 0.2 0 2.5 33
United States 2009 95.2 4.8 3.2 ND ND ND ND 17
Canada 2014 ND 0 0 ND 0 0 0 18
Canada 2000 ND 0 0 ND 0.7 0 15.7 23
Portugal 2001 81.6 0 0 ND 0 0 ND 34
Greece 2014 47.8 0 0 ND 1.5 0 28.4 24
Ethiopia 2018 94.6 ND ND 86.6 37.8 16.2 78.4 20
Tunisia 2008 95 0 0 3.8 1.25 0 12.5 21
Iran 2012 0 0 0 0 ND 0 100 25
Taiwan 2012 97.8 0 0 ND 19.8 0 18.5 2
China 2018 74.2 0 0 70.8 6.8 3.4 28.1 19
Thailand 2016 97 0 0 ND ND ND ND 16
Pakistan 2015 63 4 0 59.1 ND 59 59 13
Lebanon 2019 92.6 0 0 0 0 2.9 14.7 This study
Ampicillin (AMP); Amoxicillin - clavulanic acid (AMC); Cefotaxime (CTX); Erythromycin (E); Tetracycline (TET); 
Ciprofloxacin (CIP); Trimethoprim-sulfamethoxazole (SXT); Not determined (ND).
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M. catarrhalis isolates in Lebanon, with a higher 
rate than that reported in the majority of countries. 
Surprisingly, two studies conducted in Ethiopia and 
Pakistan showed high level of resistance to cipro-
floxacin, with 16.2% and 59% respectively [13, 20]. 
Indeed, our generated data are in accordance 
with recent national studies reporting an increased 
level of antimicrobial resistance among infectious 
bacterial agents, a striking low level of antibiotic 
awareness among Lebanese population, a spread 
of counterfeit medicines, and a misuse of antibiotics 
in Lebanon [6-11, 26-32]. Even if this study provides 
useful information for physicians to develop effec-
tive empirical antibiotic treatment for M. catarrhalis 
infections, we advise to pay attention to this promi-
nent issue and we recommend the implementation 
of reliable identification and antibiotic susceptibility 
testing in routine laboratory diagnostics to guide 
appropriate treatment.
In summary, to our knowledge, this study is the 
first investigation regarding the antimicrobial sus-
ceptibility patterns of M. catarrhalis isolates in Le-
banon. Overall, our isolates showed 100% suscep-
tibility to the majority of tested antibiotics, except 
ampicillin, trimethoprim-sulfamethoxazole, nalidixic 
acid and ciprofloxacin. Due to the limited number 
of isolates analyzed in this investigations, the epi-
demiologic significance of these results remains to 
be confirmed. Therefore, additional long-term sur-
veillance studies including a large number of isolates 
are required to assess the antimicrobial resistance of 
this important human pathogen.
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